A Phase I, Open-label Study to Assess the Safety, Tolerability and Pharmacokinetics of Ascending Doses of SH-1028 Tablets in Patients With Advanced Solid Cancer
Phase of Trial: Phase I
Latest Information Update: 06 Feb 2019
Price : $35 *
At a glance
- Drugs SH 1028 (Primary)
- Indications Non-small cell lung cancer; Solid tumours
- Focus Adverse reactions
- Sponsors Nanjing Sanhome Pharmaceutical
- 27 Jan 2019 Planned primary completion date changed from 1 Dec 2018 to 1 Dec 2019.
- 10 Oct 2018 Status changed from not yet recruiting to recruiting.
- 04 Sep 2018 Planned initiation date changed from 1 Aug 2018 to 1 Sep 2018.